First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
Clin Respir J. 2020 Nov;14(11):1090-1098. doi: 10.1111/crj.13246. Epub 2020 Aug 13.
Risk stratification for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) may help clinicians choose appropriate treatments and improve the quality of care.
A total of 695 patients hospitalized with AECOPD from January 2015 to December 2017 were considered. They were assigned to a death and a survival cohort. The independent prognostic factors were determined by multivariate logistic regression analysis. Meanwhile, we also compared the new scale with three other scores and tested the new scale internally and externally.
A new risk score was created, made up of six independent variables: age, D-dimer, albumin, cardiac troponin I, partial pressure of carbon dioxide and oxygenation index. The area under the receiver operator characteristic curve (AUROC) for the model was 0.929, and the other three CURB-65, DECAF and BAP-65 models were 0.718, 0.922 and 0.708. The Cohen's kappa coefficient between the new scale and DECAF was calculated to be 0.648, suggesting that there is a substantial consistency between the two. In the internal and external validation cohorts, 490 and 500 patients were recruited with a total mortality rate of 5.15%. The AUROC for in-hospital mortality was 0.937 in the internal cohort and 0.914 in external cohort, which was significantly better than the scores for CURB-65 and BAP-65, but it was not significantly different from the DECAF.
The new scale may help to stratify the risk of in-hospital mortality of AECOPD. The DECAF performed as well as the new instrument, and it appears to be valid in Chinese patients.
对慢性阻塞性肺疾病急性加重(AECOPD)患者进行风险分层,有助于临床医生选择合适的治疗方法,提高治疗质量。
共纳入 2015 年 1 月至 2017 年 12 月期间因 AECOPD 住院的 695 例患者,将其分为死亡组和存活组。采用多变量逻辑回归分析确定独立的预后因素。同时,我们还将新评分与其他三个评分进行了比较,并对新评分进行了内部和外部验证。
创建了一个新的风险评分,由 6 个独立变量组成:年龄、D-二聚体、白蛋白、肌钙蛋白 I、二氧化碳分压和氧合指数。模型的受试者工作特征曲线下面积(AUROC)为 0.929,而 CURB-65、DECAF 和 BAP-65 模型分别为 0.718、0.922 和 0.708。新评分与 DECAF 之间的 Cohen's kappa 系数为 0.648,表明两者之间存在显著一致性。在内部和外部验证队列中,分别纳入 490 例和 500 例患者,总死亡率为 5.15%。内部队列的住院死亡率 AUROC 为 0.937,外部队列为 0.914,均明显优于 CURB-65 和 BAP-65 评分,但与 DECAF 无显著差异。
新评分有助于分层 AECOPD 患者住院死亡率的风险。DECAF 与新仪器的性能相当,在中国患者中似乎是有效的。